The FDA requested additional clinical data from Unicycive Therapeutics.
4 reports, 3 independent
Updated Oct 30
Gone quiet
- Reports
- 4
- Developments
- 3
- Repetition
- 25%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The FDA requested additional clinical data from Unicycive Therapeutics.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.FDA issued a Complete Response Letter to Unicycive Therapeutics on its drug application.1 source
Lawsuit alleges misleading statements by Unicycive regarding FDA scrutiny.1 source
FDA requested more clinical data from Unicycive Therapeutics.1 source
Keep exploring
The entities involved
Related events
- Discussion on the limits of pharmacotherapy and the role of FDA approvals.
- FDA failed to update warning labels despite confirmed risks associated with a product.
- FDA reviewed an NDA and entered a clinical study agreement for a babesiosis trial involving 60 Degrees Pharmaceuticals.
- FDA placed a clinical hold on the drug application submitted by Bright Minds Biosciences Inc.
- Anavex Life Sciences submitted data for FDA discussions and received scientific advice from the EMA.